Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celine Mascaux

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|November 17, 2018
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung CancerMathieu Grangeon, Pascale Tomasini, Solene Chaleat, et al.
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2011
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technologyCeline Mascaux, Murry W Wynes, Yasufumi Kato, et al.
The Oncologist|March 11, 2022
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)Sanjay Popat, Te-Chun Hsia, Jen-Yu Hung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaDaniel C Christoph, Bernadette Reyna Asuncion, Celine Mascaux, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 28, 2012
Endobronchial miRNAs as biomarkers in lung cancer chemopreventionCeline Mascaux, William J Feser, Marina T Lewis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Proteogenomic Analysis of Surgically Resected Lung AdenocarcinomaMichael F Sharpnack, Nilini Ranbaduge, Arunima Srivastava, et al.
Science Translational Medicine|November 17, 2021
Assessing therapy response in patient-derived xenograftsJanosch Ortmann, Ladislav Rampášek, Elijah Tai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung AdenocarcinomaErin L Stewart, Celine Mascaux, Nhu-An Pham, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|November 17, 2018
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung CancerMathieu Grangeon, Pascale Tomasini, Solene Chaleat, et al.
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2011
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technologyCeline Mascaux, Murry W Wynes, Yasufumi Kato, et al.
The Oncologist|March 11, 2022
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)Sanjay Popat, Te-Chun Hsia, Jen-Yu Hung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaDaniel C Christoph, Bernadette Reyna Asuncion, Celine Mascaux, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 28, 2012
Endobronchial miRNAs as biomarkers in lung cancer chemopreventionCeline Mascaux, William J Feser, Marina T Lewis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Proteogenomic Analysis of Surgically Resected Lung AdenocarcinomaMichael F Sharpnack, Nilini Ranbaduge, Arunima Srivastava, et al.
Science Translational Medicine|November 17, 2021
Assessing therapy response in patient-derived xenograftsJanosch Ortmann, Ladislav Rampášek, Elijah Tai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung AdenocarcinomaErin L Stewart, Celine Mascaux, Nhu-An Pham, et al.
Pageof 3